| 2024 |
Hong, L. E., Wechalekar, M. D., Kutyna, M., Small, A., Lim, K., Thompson-Peach, C., . . . Hiwase, D. K. (2024). IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation. Blood, blood.2023023593.
DOI |
| 2023 |
Samaraweera, S. E., Geukens, T., Casolari, D. A., Nguyen, T., Sun, C., Bailey, S., . . . Ross, D. M. (2023). Novel modes of MPL activation in triple-negative myeloproliferative neoplasms. Pathology, 55(1), 77-85.
DOI |
| 2023 |
Saygin, C., Roloff, G. W., Hahn, C. N., Chhetri, R., Gill, S. I., Elmariah, H., . . . Godley, L. A. (2023). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances, 7(4), 549-554.
DOI Scopus21 WoS10 Europe PMC10 |
| 2023 |
Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091.
DOI Scopus9 WoS7 Europe PMC5 |
| 2023 |
Homan, C. C., Scott, H. S., & Brown, A. L. (2023). Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26. Blood, 141(13), 1533-1543.
DOI Scopus13 WoS4 Europe PMC9 |
| 2023 |
Flerlage, J. E., Myers, J. R., Maciaszek, J. L., Oak, N., Rashkin, S. R., Hui, Y., . . . Rampersaud, E. (2023). Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma. Blood, 141(11), 1293-1307.
DOI Scopus7 WoS4 Europe PMC5 |
| 2023 |
Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9.
DOI Scopus5 WoS2 Europe PMC4 |
| 2023 |
Zerella, J. R., Homan, C. C., Arts, P., Brown, A. L., Scott, H. S., & Hahn, C. N. (2023). Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy. Frontiers in Oncology, 13, 1-33.
DOI |
| 2023 |
Homan, C. C., Drazer, M. W., Yu, K., Lawrence, D. M., Feng, J., Arriola-Martinez, L., . . . Brown, A. L. (2023). Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Advances, 7(20), 6092-6107.
DOI Scopus8 Europe PMC6 |
| 2022 |
Feurstein, S., Luo, X., Shah, M., Walker, T., Mehta, N., Wu, D., . . . Zhang, L. (2022). Revision of RUNX1 variant curation rules. Blood Advances, 6(16), 4726-4730.
DOI Scopus6 WoS2 Europe PMC5 |
| 2022 |
Duncavage, E. J., Bagg, A., Hasserjian, R. P., DiNardo, C. D., Godley, L. A., Iacobucci, I., . . . Cazzola, M. (2022). Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood, 140(21), 2228-2247.
DOI Scopus60 WoS33 Europe PMC33 |
| 2022 |
Shah, M., Hahn, C. N., Tran, E. N. H., Sharplin, K. M., Chhetri, R., Baranwal, A., . . . Hiwase, D. (2022). <i>TP53</i> Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome. BLOOD, 140(Supplement 1), 9798-9799.
DOI |
| 2022 |
Tawana, K., Brown, A. L., & Churpek, J. E. (2022). Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges. British Journal of Haematology, 196(6), 1293-1310.
DOI Scopus28 WoS21 Europe PMC17 |
| 2022 |
Brown, A. L. (2022). And the germline beat (AML) goes on. Blood, 139(8), 1126-1128.
DOI |
| 2022 |
Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
DOI Scopus19 WoS9 Europe PMC14 |
| 2022 |
Drazer, M. W., Homan, C. C., Yu, K., Cavalcante de Andrade Silva, M., McNeely, K. E., Pozsgai, M. J., . . . Godley, L. A. (2022). Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations.. Blood Adv, 6(15), 4357-4359.
DOI Scopus12 WoS4 Europe PMC7 |
| 2022 |
Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12.
DOI Scopus8 WoS8 Europe PMC7 |
| 2022 |
Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131.
DOI Scopus1 WoS1 |
| 2021 |
Homan, C. C., Venugopal, P., Arts, P., Shahrin, N. H., Feurstein, S., Rawlings, L., . . . Hahn, C. N. (2021). GATA2 deficiency syndrome: a decade of discovery. Human Mutation, 42(11), 1399-1421.
DOI Scopus24 WoS13 Europe PMC20 |
| 2021 |
Six, K. A., Gerdemann, U., Brown, A. L., Place, A. E., Cantor, A. B., Kutny, M. A., & Avagyan, S. (2021). B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations. Blood Advances, 5(16), 3199-3202.
DOI Scopus10 WoS5 Europe PMC9 |
| 2021 |
Avagyan, S., & Brown, A. L. (2021). To T or not to B: Germline RUNX1 mutation preferences in pediatric ALL predisposition. Journal of Clinical Investigation, 131(17), 4 pages.
DOI Scopus4 WoS3 Europe PMC4 |
| 2021 |
Samaraweera, S. E., Wang, P. P. S., Li, K. L., Casolari, D. A., Feng, J., Pinese, M., . . . D'Andrea, R. J. (2021). Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 138(22), 2293-2298.
DOI Scopus5 WoS5 Europe PMC5 |
| 2021 |
Corboy, G., Othman, J., Lee, L., Wei, A., Ivey, A., Blombery, P., . . . Stevenson, W. (2021). Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 53(4), 487-492.
DOI |
| 2021 |
Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
DOI Scopus34 WoS26 Europe PMC25 |
| 2021 |
Homan, C. C., King-Smith, S. L., Lawrence, D. M., Arts, P., Feng, J., Andrews, J., . . . Brown, A. L. (2021). The RUNX1 Database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.. Haematologica, 106(11), 3004-3007.
DOI Scopus27 WoS20 Europe PMC13 |
| 2021 |
Homan, C. C., Venugopal, P., Arts, P., Shahrin, N. H., Feurstein, S., Rawlings, L., . . . Hahn, C. N. (2021). Cover, Volume 42, Issue 11. Human Mutation, 42(11).
DOI |
| 2020 |
Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C. -E., . . . Scott, H. S. (2020). RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 4(6), 1131-1144.
DOI Scopus89 WoS65 Europe PMC57 |
| 2020 |
Brown, A. L., Hahn, C. N., & Scott, H. S. (2020). Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood, 136(1), 24-35.
DOI Scopus63 WoS49 Europe PMC50 |
| 2020 |
Fox, L. C., Tan, M., Brown, A. L., Arts, P., Thompson, E., Ryland, G. L., . . . Blombery, P. (2020). A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. British Journal of Haematology, 190(5), e297-e301.
DOI Scopus12 WoS12 Europe PMC9 |
| 2020 |
Brown, A. L., & Hiwase, D. K. (2020). What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening. Leukemia Research, 96, 3 pages.
DOI Scopus3 WoS3 Europe PMC1 |
| 2020 |
Brown, A. L., Hahn, C., Hiwase, D., Godley, L. A., & Scott, H. S. (2020). Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. LEUKEMIA & LYMPHOMA, 61(1), 2 pages.
DOI Scopus2 WoS2 Europe PMC1 |
| 2020 |
Venugopal, P., Gagliardi, L., Forsyth, C., Feng, J., Phillips, K., Babic, M., . . . Scott, H. S. (2020). Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss. BMC Medical Genetics, 21(1), 35-1-35-5.
DOI Scopus3 WoS2 Europe PMC2 |
| 2019 |
Cheah, J. J. C., Brown, A. L., Schreiber, A. W., Feng, J., Babic, M., Moore, S., . . . Scott, H. S. (2019). A novel germline SAMD9L mutation in a family with ataxia-pancytopenia syndrome and pediatric acute lymphoblastic leukemia. Haematologica, 104(7), e318-e321.
DOI Scopus13 WoS12 Europe PMC11 |
| 2019 |
Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J. K., Shi, L., Pounds, S. B., . . . Mullighan, C. G. (2019). Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature genetics, 51(4), 694-704.
DOI Scopus93 WoS68 Europe PMC67 |
| 2019 |
Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853.
DOI Scopus41 WoS38 Europe PMC25 |
| 2019 |
Luo, X., Feurstein, S., Mohan, S., Porter, C. C., Jackson, S. A., Keel, S., . . . Godley, L. A. (2019). ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Advances, 3(20), 2962-2979.
DOI Scopus96 WoS80 Europe PMC61 |
| 2018 |
Beck, D., Thoms, J., Palu, C., Herold, T., Shah, A., Olivier, J., . . . Pimanda, J. (2018). A four-gene lincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. Leukemia, 32(2), 263-272.
DOI Scopus33 WoS30 Europe PMC19 |
| 2018 |
Chong, C. -E., Venugopal, P., Stokes, P., Lee, Y., Brautigan, P., Yeung, D., . . . Scott, H. (2018). Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. Leukemia, 32(1), 194-202.
DOI Scopus45 WoS40 Europe PMC30 |
| 2018 |
Maung, K. Z. Y., Leo, P. J., Bassal, M., Casolari, D. A., Gray, J. X., Bray, S. C., . . . Gonda, T. J. (2018). Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia. Blood Cancer Journal, 8(6), 50-1-50-5.
DOI Scopus15 WoS14 Europe PMC11 |
| 2018 |
Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961.
DOI Scopus136 WoS121 Europe PMC95 |
| 2017 |
Cheah, J., Hahn, C., Hiwase, D., Scott, H., & Brown, A. (2017). Myeloid neoplasms with germline DDX41 mutation. International Journal of Hematology, 106(2), 163-174.
DOI Scopus72 WoS59 Europe PMC52 |
| 2017 |
Maciejewski, J. P., Padgett, R. A., Brown, A. L., & Müller-Tidow, C. (2017). DDX41-related myeloid neoplasia. Seminars in Hematology, 54(2), 94-97.
DOI Scopus39 WoS39 Europe PMC31 |
| 2017 |
Brown, A. L., Churpek, J. E., Malcovati, L., Döhner, H., & Godley, L. A. (2017). Recognition of familial myeloid neoplasia in adults. Seminars in Hematology, 54(2), 60-68.
DOI Scopus33 WoS29 Europe PMC23 |
| 2017 |
Gill, D., Del Greco M, F., Rawson, T. M., Sivakumaran, P., Brown, A., Sheehan, N. A., & Minelli, C. (2017). Age at Menarche and Time Spent in Education: A Mendelian Randomization Study. Behavior Genetics, 47(5), 480-485.
DOI Scopus18 Europe PMC14 |
| 2016 |
Lewinsohn, M., Brown, A. L., Weinel, L. M., Phung, C., Rafidi, G., Lee, M. K., . . . Scott, H. S. (2016). Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood, 127(8), 1017-1023.
DOI Scopus162 WoS141 Europe PMC118 |
| 2016 |
Lynch, J. R., Yi, H., Casolari, D. A., Voli, F., Gonzales-Aloy, E., Fung, T. K., . . . Wang, J. Y. (2016). Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia. Leukemia, 30(8), 1745-1748.
DOI Scopus7 WoS5 Europe PMC6 |
| 2016 |
Shahrin, N., Diakiw, S., Dent, L., Brown, A., & D'Andrea, R. (2016). Conditional knockout mice demonstrate function of Klf5 as a myeloid transcription factor. Blood, 128(1), 55-59.
DOI Scopus24 WoS25 Europe PMC22 |
| 2016 |
Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F., . . . Mason, C. E. (2016). Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 22(7), 792-799.
DOI Scopus272 WoS247 Europe PMC212 |
| 2015 |
Hahn, C., Ross, D., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W., . . . Scott, H. (2015). A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 29(10), 2101-2104.
DOI Scopus26 WoS23 Europe PMC22 |
| 2015 |
Forristal, C. E., Brown, A. L., Helwani, F. M., Winkler, I. G., Nowlan, B., Barbier, V., . . . Levesque, J. P. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085.
DOI Scopus30 WoS27 Europe PMC31 |
| 2014 |
Perugini, M., Samaraweera, S. E., Brown, A. L., Cummings, N., Danner, S., Tiong, I. S., . . . D'Andrea, R. J. (2014). The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. BLOOD, 124(21), 3 pages. |
| 2014 |
Li, S., Garrett-Bakelman, F., Perl, A., Luger, S., Zhang, C., To, B., . . . Mason, C. (2014). Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology, 15(9), 472-1-472-12.
DOI Scopus54 WoS56 Europe PMC46 |
| 2013 |
Li, S., Garrett-Bakelman, F., Akalin, A., Zumbo, P., Levine, R., To, L., . . . Mason, C. (2013). An optimized algorithm for detecting and annotating regional differential methylation. BMC Bioinformatics, 14(supp 5), 1-9.
DOI Scopus91 WoS84 Europe PMC54 |
| 2013 |
Diakiw, S., D'Andrea, R., & Brown, A. (2013). The double life of KLF5: Opposing roles in regulation of gene-expression, cellular function, and transformation. IUBMB Life, 65(12), 999-1011.
DOI Scopus48 WoS38 Europe PMC32 |
| 2013 |
Perugini, M., Iarossi, D., Kok, C., Cummings, N., Diakiw, S., Brown, A., . . . D'Andrea, R. (2013). GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. Leukemia, 27(7), 1588-1592.
DOI Scopus19 WoS18 Europe PMC13 |
| 2013 |
Diakiw, S., Perugini, M., Kok, C., Engler, G., Cummings, N., To, L., . . . D'Andrea, R. (2013). Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. British Journal of Haematology, 161(6), 884-888.
DOI Scopus17 WoS15 Europe PMC12 |
| 2013 |
Kok, C., Brown, A., Perugini, M., Iarossi, D., Lewis, I., & D'Andrea, R. (2013). The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: A combined analysis of 1053 core-binding factor AML patients. British Journal of Haematology, 160(4), 557-559.
DOI Scopus9 WoS10 Europe PMC8 |
| 2012 |
Diakiw, S., Kok, C., To, L., Lewis, I., Brown, A., & D'Andrea, R. (2012). The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. Leukemia Research, 36(1), 110-116.
DOI Scopus22 WoS21 Europe PMC20 |
| 2012 |
Brown, A., Salerno, D., Sadras, T., Engler, G., Kok, C., Wilkinson, C., . . . D'Andrea, R. (2012). The GM-CSF receptor utilizes β-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation, 83(1), 47-59.
DOI Scopus21 WoS16 Europe PMC14 |
| 2012 |
White, D. L., Brown, A. L., D'Andrea, R. J., & Rice, A. M. (2012). Unraveling the "known unknowns": lessons and reflections from the new directions in leukemia research 2012 conference. Cancer Research, 72(17), 4300-4303.
DOI |
| 2011 |
Hahn, C., Chong, C., Carmichael, C., Wilkins, E., Brautigan, P., Li, X., . . . Scott, H. (2011). Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genetics, 43(10), 1012-1019.
DOI Scopus482 WoS424 Europe PMC352 |
| 2010 |
Kok, C., Brown, A., Ekert, P., & D'Andrea, R. (2010). Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML. Leukemia, 24(6), 1239-1243.
DOI Scopus13 WoS12 Europe PMC10 |
| 2010 |
Perugini, M., Brown, A., Salerno, D., Booker, G., Stojkoski, C., Hercus, T., . . . D'Andrea, R. (2010). Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common β-subunit. Blood, 115(16), 3346-3353.
DOI Scopus54 WoS47 Europe PMC32 |
| 2009 |
Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870.
DOI Scopus52 WoS49 Europe PMC41 |
| 2009 |
Perugini, M., Kok, C., Brown, A., Wilkinson, C., Salerno, D., Young, S., . . . D'Andrea, R. (2009). Repression of Gadd45α by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation. Leukemia, 23(4), 729-738.
DOI Scopus19 WoS17 Europe PMC14 |
| 2009 |
Eppley, S. M., O'Quinn, R., & Brown, A. L. (2009). New sequence-tagged site molecular markers for identification of sex in Distichlis spicata. Molecular Ecology Resources, 9(5), 1373-1374.
DOI Scopus6 |
| 2006 |
Brown, A., Wilkinson, C., Waterman, S., Kok, C., Salerno, D., Diakiw, S., . . . D'Andrea, R. (2006). Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. Journal of Leukocyte Biology, 80(2), 433-447.
DOI Scopus35 WoS31 Europe PMC26 |
| 2005 |
Phan, V. T., Shultz, D. B., Truong, B. T. H., Blake, T. J., Brown, A. L., Gonda, T. J., . . . Kogan, S. C. (2005). Erratum: Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation (Molecular and Cellular Biology (2003) 23, 13 (4573-4585)). Molecular and Cellular Biology, 25(13), 5787.
DOI |
| 2004 |
Brown, A., Peters, M., D'Andrea, R., & Gonda, T. (2004). Constitutive mutants of the GM-CSF receptor reveal multiple pathways leading to myeloid cell survival, proliferation, and granulocyte-macrophage differentiation. Blood, 103(2), 507-516.
DOI Scopus14 WoS16 Europe PMC10 |
| 2003 |
Phan, V., Shultz, D., Truong, B., Blake, T., Brown, A., Gonda, T., . . . Kogan, S. (2003). Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation. Molecular and Cellular Biology, 23(13), 4573-4585.
DOI Scopus12 WoS9 Europe PMC9 |
| 2001 |
Browes, C., Rowe, J., Brown, A., & Montano, X. (2001). Analysis of trk A and p53 association. FEBS Letters, 497(1), 20-25.
DOI Scopus9 Europe PMC7 |
| 2000 |
Lemercier, C., Brown, A., Mamani, M., Ripoche, J., & Reiffers, J. (2000). The rat Mist1 gene: Structure and promoter characterization. Gene, 242(1-2), 209-218.
DOI Scopus7 Europe PMC6 |
| 2000 |
Brown, A., Browes, C., Mitchell, M., & Montano, X. (2000). c-abl is involved in the association of p53 and trk A. Oncogene, 19(26), 3032-3040.
DOI Scopus20 Europe PMC13 |
| 1999 |
Brown, A. L., & Kay, G. F. (1999). Corrigendum: Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome (Human Molecular Genetics (1999) 8 (611-619)). Human Molecular Genetics, 8(5), 943.
Scopus1 |
| 1999 |
Brown, A. L., & Kay, G. F. (1999). Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome. Human Molecular Genetics, 8(4), 611-619.
DOI Scopus55 WoS56 Europe PMC39 |
| 1997 |
Sharrocks, A. D., Brown, A. L., Ling, Y., & Yates, P. R. (1997). The ETS-domain transcription factor family. International Journal of Biochemistry and Cell Biology, 29(12), 1371-1387.
DOI Scopus288 Europe PMC191 |
